

SR-717 free acid Biochemical | SR-717 biochemical

SR-717 free acid

CATALOG #
AAA228359


PRODUCT SYNONYMS

SR-717 free acid; SR-717 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2375420-34-9
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	SR-717 (30 mg/kg intraperitoneal once-per-day for 1 week) shows antitumor activities in WT or Sting gt/gt mice[1]. SR-717 (30 mg/kg intraperitoneally for 7 days) displays antitumor activity; promotes the activation of CD8 + T, natural killer, and dendritic cells in relevant tissues; and facilitates antigen cross-priming[1]. Animal Model: WT or Sting gt/gt mice[1]. Dosage: 30 mg/kg. Administration: Intraperitoneally; once-per-day for 1 week. Result: Maximally inhibited tumor growth.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
CP-628006, CAS 305822-08-6



Structure
CP-628006, CAS 305822-08-6

ADDITIONAL INFORMATION

Related Product Information for SR-717 biochemical	SR-717 free acid is a non-nucleotide STING agonist with EC 50 s of 2.1 uM and 2.2 uM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 free acid is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity.
References	1. Liu J, et al. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR. Br J Pharmacol. 2021 Oct 13.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

